Pharmaceutical Summit on Business & Compliance Issues in Managed Markets
The Pharmaceutical Summit on Business and Compliance Issues in Managed Markets is set to take place June 8 through June 9, 2016, at the Grand Hyatt in Washington, D.C.
The conference opens on the morning of June 8, 2016, with a preconference workshop, with an introductory workshop that provides an overview of the United States payment systems for pharmaceuticals.
Day One officially starts at 1:00 pm on June 8, 2016, with a welcome by Susan Dentzer, which leads into a presentation by Robert Dubois, MD, PhD, on how to develop and use value-based frameworks for pharmaceuticals and guiding standards for how to implement those frameworks.
The afternoon continues, including a keynote presentation by Gregg Shapiro, the Assistant United States Attorney for the US Attorney's Office in the District of Massachusetts, on a prosecutor's perspective on enforcement actions. Day One ends with a panel on compliance and legal considerations within the managed markets business, with presentations by Blake Bolinger, the Director of US Pharmaceuticals, Compliance and Ethics, at Bristol-Myers Squibb; Jennifer McGee, the interim chief compliance officer and senior compliance counsel at Otsuka Pharmaceutical Development and Commercialization, Inc; Ronald Wisor, a partner at Hogan Lovells; and Seth Lundy, a partner at King and Spalding.
Day Two starts with two different tracks: Track A will discuss 340B program considerations and attendees will hear from Anthony Greco, a Director of Pharmaceutical & Life Sciences Advisory Services at PwC; Ray Schroeder, a Director of Pharmaceutical & Life Sciences Advisory Services at PwC; and Aaron Vandervelde, the Managing Director of the Berkeley Research Group. Track B attendees will hear about real world evidence and implications to value-based contracting, presented by Mark DeWyngaert, the managing director of Huron Life Sciences.
The morning continues with several other track options, including: legal and regulatory challenges regarding risk-sharing arrangements in the journey to value-based care, how to optimize contract operations through technology and harness insights through analytics to drive strategy and compliance, and what some of the strategic precursors are that are necessary for value-based contracting approaches to take hold.
Day Two closes out with a discussion on the future of the United States pharmaceutical marketplace, including PhRMA's perspective and how to manage communications between manufacturers and payers.
If you are interested in attending this conference, those who register by May 20, 2016, can qualify for the $200 Early Bird discount. Registration information can be found here.